ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
ESC Heart Failure 2023
Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
- Ahmad Masri, MD
Benefits of rapid uptitration of HF medications independent of baseline renal function
Benefits of rapid uptitration of HF medications independent of baseline renal function
ESC Heart Failure 2023
Benefits of rapid uptitration of HF medications independent of baseline renal function
- Jozine ter Maaten, MD, PhD
Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
ESC Heart Failure 2023
Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
- Jasper Brugts, MD, PhD
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
ESC Heart Failure 2023
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
- Marianna Fontana, MD, PhD